Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Next Previous
Search
Trial Profile

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narmafotinib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACCENT
  • Sponsors Amplia Therapeutics Limited

Most Recent Events

  • 27 Mar 2025 According to Amplia Therapeutics Limited Media Release, further data from the ACCENT trial has been accepted for presentation at the annual meeting of American Association of Cancer Research (AACR) to be held next month in Chicago.
  • 27 Mar 2025 Results presented in the Amplia Therapeutics Media Release.
  • 19 Feb 2025 According to Amplia Therapeutics Limited Media Release, data from this ongoing ACCENT trial in pancreatic cancer, was presented overnight at the prestigious Keystone meeting Tumor Microenvironment: Metastasis and the Host in Banff, Canada.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top